… The OAI Imaging Working Group was composed of the following individuals: Charles Peterfy
MD PhD (chair), and in alphabetical order, Mostafa Analoui PhD, Fernando Boada PhD, …

One of the critical challenges in developing structure-modifying therapies for arthritis, especially
osteoarthritis (OA), is measuring changes in progression of joint destruction. Magnetic …

Objectives: To describe a semi-quantitative scoring method for multi-feature, whole-organ
evaluation of the knee in osteoarthritis (OA) based on magnetic resonance imaging (MRI) …

Objective More timely and effective therapy for rheumatoid arthritis (RA) has contributed to
increasing rates of clinical remission. However, progression of structural damage may still …

Objective Achieving remission is the aim of treatment in rheumatoid arthritis (RA). This
should represent minimal arthritis activity and ensure optimal disease outcome. However, we …

Knee osteoarthritis (OA) is a leading cause of disability. Recent advances in drug discovery
techniques and improvements in understanding the pathophysiology of osteoarthritic …

… Peterfy owns stock or stock options in Synarc, a company that provides centralized image
and biochemical analysis services and subject recruitment for clinical trials to pharmaceutical, …

The purpose of this study was to assess the accuracy of routine T2-weighted MR imaging in
detecting and grading articular cartilage lesions in the knee compared with arthroscopy. We …

PURPOSE: To assess the reproducibility and accuracy of volumetric quantifications of
articular cartilage in the knee determined with three-dimensional (3D) magnetic resonance (MR) …

Objectives Rituximab is an effective treatment in patients with established rheumatoid arthritis
(RA). The objective of the IMAGE study was to determine the efficacy of rituximab in the …